FK949E
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bipolar Disorder
Conditions
Bipolar Disorder, Elderly
Trial Timeline
Oct 29, 2012 → Jun 29, 2016
NCT ID
NCT01737268About FK949E
FK949E is a phase 3 stage product being developed by Astellas Pharma for Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01737268. Target conditions include Bipolar Disorder, Elderly.
What happened to similar drugs?
20 of 20 similar drugs in Bipolar Disorder were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02362412 | Phase 3 | Completed |
| NCT01737268 | Phase 3 | Completed |
| NCT01919008 | Phase 1 | Completed |
| NCT01924520 | Phase 1 | Completed |
| NCT01903200 | Phase 1 | Completed |
| NCT01871987 | Phase 1 | Completed |
| NCT01871974 | Phase 1 | Completed |
Competing Products
20 competing products in Bipolar Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine | Eli Lilly | Phase 3 | 32 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 40 |
| Olanzapine + Placebo | Eli Lilly | Approved | 43 |
| FK949E | Astellas Pharma | Phase 3 | 40 |
| FK949E + Placebo | Astellas Pharma | Phase 2/3 | 38 |
| Escitalopram + Bupropion XL | Lupin Limited | Phase 3 | 32 |
| Olanzapine | Eli Lilly | Approved | 43 |
| Olanzapine Hydrochloride + Lithium Carbonate | Eli Lilly | Phase 3 | 40 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 40 |
| Olanzapine | Eli Lilly | Approved | 43 |
| Olanzapine | Eli Lilly | Phase 3 | 40 |
| LY2979165 + Placebo | Eli Lilly | Phase 1 | 29 |
| olanzapine + divalproex sodium + placebo | Eli Lilly | Approved | 43 |
| olanzapine + risperidone | Eli Lilly | Approved | 43 |
| LY2979165 + placebo | Eli Lilly | Phase 1 | 29 |
| Topiramate + Placebo | Eli Lilly | Approved | 43 |
| olanzapine | Eli Lilly | Phase 3 | 40 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 40 |
| Brenipatide + Placebo | Eli Lilly | Phase 2 | 42 |
| Olanzapine Fluoxetine Combination (OFC) + Placebo | Eli Lilly | Approved | 43 |